Ceribell CEO and CFO to speak at two March investor conferences
Ceribell (Nasdaq: CBLL) announced that its CEO, Jane Chao, and CFO, Scott Blumberg, will present at two investor conferences in March 2026. CFO Blumberg will speak at the Raymond James 47th Annual Institutional Investors Conference on March 2, while both executives will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3. Webcasts of these events will be available on the company's Investor Relations website.
CenterBook Partners LP Increases Stake in CeriBell, Inc. $CBLL
CenterBook Partners LP significantly increased its stake in CeriBell, Inc. (NASDAQ:CBLL) by 448% during the third quarter, now owning 1.28% of the company valued at approximately $5.48 million. Other institutional investors like JPMorgan Chase & Co. and Vanguard Group Inc. also adjusted their positions. Despite insider selling activity, CeriBell maintains a "Moderate Buy" consensus rating from analysts with an average target price of $24.67.
CeriBell (CBLL) Projected to Post Earnings on Tuesday
CeriBell (NASDAQ:CBLL) is anticipated to release its Q4 2025 earnings before market open on Tuesday, February 24th, with analysts projecting a loss of ($0.43) per share. Recent insider selling activity by Director Josef Parvizi and CTO Raymond Woo totaled over $7.28 million, despite insiders still owning 20.10% of the company. Analysts hold a "Moderate Buy" consensus rating for CeriBell, with an average price target of $24.67.
CeriBell, Inc. (CBLL) Stock Analysis: A 41% Upside Potential In Revolutionary Medical Devices
CeriBell, Inc. (CBLL), a medical device company specializing in neurological diagnostics, is highlighted for its innovative EEG technology and strong growth potential despite current unprofitability. Analysts are bullish, with eight buy ratings and an average target price suggesting a 41% upside. The company's Ceribell System, featuring AI-powered seizure detection, positions it as a key player in advancing critical care diagnostics.
Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Ceribell, Inc. announced it will release its fourth-quarter and full-year 2025 financial results on February 24, 2026, after market close. The company will host a conference call on the same day at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. Ceribell is a medical technology company specializing in the diagnosis and management of severe neurological conditions using its FDA-cleared Ceribell System.
Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Ceribell, Inc. (Nasdaq: CBLL) announced it will release its fourth quarter and full year 2025 financial results on February 24, 2026, after the close of trading. The medical technology company, which specializes in neurological condition diagnosis and management, will also host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. Investors can access the call via phone or a webcast on the company’s investor relations website.
Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Ceribell announced it will release its financial results for the fourth quarter and full year of 2025 after market close on Tuesday, February 24, 2026. Company management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results, with investors able to access the call via a dial-in number or webcast. Ceribell is a medical technology company focused on neurological conditions, developing an FDA-cleared point-of-care EEG system.
Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Ceribell, Inc. (Nasdaq: CBLL) announced it will release its fourth-quarter and full-year 2025 financial results on February 24, 2026, after market close. The company will host a conference call on the same day at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. Ceribell is a medical technology company focused on neurological conditions, known for its FDA-cleared Ceribell System for detecting seizure and delirium.
Ceribell Inc introduces new neonatal EEG at NEO Pediatrix event
Ceribell, Inc. will showcase its new neonatal point-of-care EEG device at the upcoming NEO Pediatrix Conference in Las Vegas. The device, designed for young patients at risk of non-convulsive seizures, will be the focus of an educational breakfast symposium led by Dr. Elissa Yozawitz. Attendees are encouraged to register for the symposium to learn more about this advancement in neonatal care.
Ceribell, Inc. shows power of POCEEG in seizure detection
Ceribell, Inc. is highlighting its POCEEG technology's critical role in rapid seizure detection. A recent case study at ISC26 demonstrated how POCEEG swiftly identified suspected non-convulsive status epilepticus in a stroke code patient, allowing for timely treatment decisions. The company emphasizes that POCEEG significantly improves the speed and accuracy of seizure detection, making it a game-changer in medical diagnostics.
CeriBell, Inc. (NASDAQ:CBLL) Given Consensus Recommendation of "Moderate Buy" by Brokerages
CeriBell, Inc. (NASDAQ:CBLL) has received a "Moderate Buy" consensus recommendation from seven brokerages, with an average one-year price target of $24.67. Despite significant insider selling over the past 90 days, including a substantial sale by the CEO, institutional investors have increased their holdings. The company, specializing in newborn hearing screening devices, reported mixed fundamentals with negative trailing earnings but exceeded analyst revenue expectations in its last quarterly report.
CeriBell (NASDAQ:CBLL) VP David Foehr Sells 5,556 Shares
CeriBell (NASDAQ:CBLL) VP David Foehr sold 5,556 shares of the company's stock on February 3rd for $111,120, reducing his stake by 22.72%. This sale continues a pattern of insider selling over recent months. Despite the insider dispositions, CeriBell carries a consensus "Moderate Buy" analyst rating with a target price of $24.67 per share.
New medical partner
This article discusses how artificial intelligence (AI) is transforming healthcare in Northwest Indiana, augmenting rather than replacing human expertise. It highlights practical applications of AI in diagnostics, such as rapid seizure detection and stroke care, and in administrative tasks, like voice recognition for medical notes, which reduce physician burnout and improve patient interaction. Regional health experts emphasize a cautious, evidence-based approach to AI implementation, ensuring privacy and maintaining human oversight in clinical decision-making.
BTIG Reiterates Buy Rating for CeriBell (CBLL) with $30 Price Ta
BTIG has reiterated its Buy rating for CeriBell (CBLL), maintaining a price target of $30, indicating continued confidence in the company. This decision aligns with a largely positive sentiment from other analysts, despite some recent adjustments in price targets. CeriBell, a medical technology company, specializes in a novel point-of-care EEG platform for diagnosing and managing neurological conditions.
CeriBell, Inc. $CBLL Shares Acquired by Emerald Mutual Fund Advisers Trust
Emerald Mutual Fund Advisers Trust significantly increased its holding in CeriBell, Inc. (NASDAQ:CBLL) by 58.2%, now owning 155,360 shares valued at $1.785 million. This comes amidst other institutional investors also boosting their stakes. Despite heavy insider selling, including CEO Xingjuan Chao's sale of 79,000 shares, analysts maintain a "Moderate Buy" consensus rating with an average price target of $24.67.
CeriBell, Inc. (CBLL) Stock Analysis: A 24% Potential Upside Beckons in the Dynamic Medical Device Sector
CeriBell, Inc. (NASDAQ: CBLL) is presented as an intriguing investment opportunity in the medical device sector, despite current negative financials. The company's innovative Ceribell System and AI-powered Clarity algorithm for neurological conditions have attracted unanimous buy ratings from analysts. With a potential upside of approximately 24.03% and strong revenue growth, CeriBell targets growth-oriented investors betting on long-term success in transforming neurological care.
Josef Parvizi Sells 25,000 Shares of CeriBell (NASDAQ:CBLL) Stock
Director Josef Parvizi sold 25,000 shares of CeriBell (NASDAQ:CBLL) stock on January 15th for $573,500, reducing his ownership by 3.24%. This is part of a series of recent sales totaling 75,000 shares. CeriBell shares were trading down 2.2% at $21.45, and analysts maintain a "Moderate Buy" rating with a consensus price target of $24.67.
Ceribell director Parvizi sells $573k in shares
Ceribell director Josef Parvizi sold 25,000 shares of common stock for $573,500 on January 15, 2026, under a pre-arranged trading plan. Despite not being profitable in the past year, Ceribell maintains impressive gross profit margins and has low debt, with analyst price targets suggesting potential upside. The company also recently received Breakthrough Device Designation for its LVO stroke detection monitor and had BTIG reiterate a Buy rating.
FDA clearances: Siemens Healthineers, Medtronic, CeriBell
This article reports on recent FDA clearances granted to Siemens Healthineers, Medtronic, and CeriBell. While the specific details of each clearance are not provided in this snippet, the headline indicates these companies have received approval for new medical devices. The article also touches on other significant industry news such as the release of the Wegovy pill and Boston Scientific's planned acquisition of Penumbra.
FDA clearances: Siemens Healthineers, Medtronic, CeriBell
The article reports on recent FDA clearances for products from Siemens Healthineers, Medtronic, and CeriBell. No specific details about the products or clearances are provided within the body of the text. It also includes sections for other featured healthcare news about politics, mergers, and staffing.
CeriBell Maps 2026 Growth at JPMorgan MedTech, Eyes Delirium and Stroke EEG Expansion
CeriBell (NASDAQ:CBLL) detailed its 2026 growth strategy at a JPMorgan MedTech event, focusing on expanding its neuromonitoring platform for acute-care seizure detection and new EEG-based applications for delirium and stroke. The company projects $87-$89 million in 2025 revenue, driven by 34% year-over-year growth and an expanded total addressable market of $3.5 billion. Key priorities for 2026 include scaling sales, securing FedRAMP High access for VA hospitals, and commercializing its FDA-cleared delirium detection tool, targeting a full launch in late 2026 or early 2027.
CeriBell Maps 2026 Growth at JPMorgan MedTech, Eyes Delirium and Stroke EEG Expansion
CeriBell showcased its 2026 growth strategy at the JPMorgan MedTech event, focusing on expanding its neuromonitoring platform for acute-care seizure detection and new indications like delirium and stroke monitoring. The company reported $87-$89 million in 2025 revenue with an 88% gross margin, expanding its total addressable market to $3.5 billion. Key 2026 priorities include scaling sales, securing FedRAMP High access for VA hospitals, and commercializing its FDA-cleared delirium detection tool with a full launch planned for Q4 2026 or early 2027.
CBLL: FDA-cleared AI neuromonitoring expands to pediatrics and delirium, driving growth and efficiency
Ceribell (CBLL) demonstrated strong growth by expanding its AI neuromonitoring platform with new FDA clearances for pediatric, neonate, and delirium detection, increasing its Total Addressable Market (TAM) to $3.5 billion. The company plans to capitalize on this expansion through an enhanced sales force and new product launches in 2026, aiming for greater market penetration and operational efficiency. This information is based on their presentation at the 44th Annual J.P. Morgan Healthcare Conference.
Ceribell sues Natus Medical for patent infringement
This system message indicates that the content for the specified article was not provided. As a result, no summary or cleaned content can be generated.
CeriBell, Inc.'s (NASDAQ:CBLL) Shares May Have Run Too Fast Too Soon
CeriBell, Inc. (NASDAQ:CBLL) has a high price-to-sales (P/S) ratio of 10.5x, significantly above the Medical Equipment industry average, suggesting its shares may be overvalued. While the company has shown strong revenue growth in the past, analysts predict its future revenue growth will lag behind the industry. This discrepancy between market valuation and future growth projections raises concerns about the sustainability of CeriBell's current stock price.
CeriBell, Inc.'s (NASDAQ:CBLL) Shares May Have Run Too Fast Too Soon
CeriBell, Inc. (NASDAQ:CBLL) has a high price-to-sales (P/S) ratio of 10.5x, significantly above the Medical Equipment industry average, which suggests its shares may be overvalued. While the company has shown strong recent revenue growth, analysts forecast future revenue growth at 29% annually, which is weaker than the industry's predicted 114% growth. This disparity raises concerns that the current high P/S ratio may not be sustainable, as investor bullishness seems to exceed analyst expectations for revenue growth.
Analysts’ Top Healthcare Picks: Ceribell, Inc. (CBLL), Evommune, Inc. (EVMN)
Two analysts have issued bullish sentiments on healthcare companies Ceribell, Inc. (CBLL) and Evommune, Inc. (EVMN). Ceribell received a Strong Buy consensus with an 11.4% upside to its price target, while Evommune also earned a Strong Buy consensus. Analysts see positive prospects for these companies within the healthcare sector.
Ceribell director resigns to pursue other professional ventures
A director at Ceribell has resigned from their position to pursue other professional opportunities. This article, published by MSN, simply notes the departure without providing further details about the director or the company.
Ceribell’s AI Stroke Detection Tool Gains FDA Breakthrough Status
Ceribell Inc. has received FDA breakthrough device designation for its LVO Stroke detection tool, which builds on its existing EEG technology. This advancement will allow for the swift identification of early signs of large vein occlusion (LVO) strokes in hospitalized patients, potentially revolutionizing stroke care and accelerating treatment. The company’s stock rose 4% following the announcement, reflecting investor confidence in this critical tool which addresses the need for timely interventions in the 75,000 strokes occurring annually in hospital settings.
Ceribell Gets FDA Breakthrough Nod For Stroke Detection, Monitoring Solution
Ceribell has received FDA Breakthrough Device designation for its AI-powered solution designed for large vessel occlusion (LVO) stroke detection and monitoring. This expands its existing point-of-care EEG brain monitoring platform, allowing for faster development and regulatory review for a technology that addresses a critical unmet medical need. The system uses an AI algorithm to interpret brain signals, aiming to improve timely diagnosis and continuous neurological monitoring for LVO strokes.
Ceribell Gets FDA Breakthrough Device Status
Ceribell has received FDA Breakthrough Device Designation for its AI-powered large vessel occlusion (LVO) stroke detection and monitoring solution. This system leverages Ceribell's existing EEG hardware and an AI-based algorithm to identify LVO strokes early, aiming to reduce treatment delays. The designation follows recent FDA 510(k) clearances for Ceribell's other technologies related to seizure detection in neonates and delirium screening, further solidifying its position in the point-of-care EEG market.
CBLL Wins FDA Breakthrough Status for AI-Based LVO Stroke Detection
CeriBell Inc. (CBLL) has received FDA Breakthrough Device Designation for its AI-based Large Vessel Occlusion (LVO) stroke detection and monitoring solution. This designation is expected to accelerate regulatory approval and commercialization, expanding Ceribell's market beyond seizure and delirium detection into high-acuity stroke care. The company's stock rose 1.4% following the announcement, building on a 21% gain over the last six months.
Ceribell receives US FDA Breakthrough Device designation for in-hospital LVO stroke detection monitor
Ceribell has been granted Breakthrough Device designation by the US FDA for its large vessel occlusion (LVO) stroke detection monitor, which uses AI-based algorithms and existing hardware to interpret EEG signals for early detection of LVO stroke in hospital settings. This designation recognizes the monitor's potential for timely and accurate LVO detection, addressing the challenges of identifying strokes in non-specialized hospital units. The company aims to make EEG a "new vital sign for better brain care," building on previous FDA clearances for their technology in other indications.
CBLL Wins FDA Breakthrough Status for AI-Based LVO Stroke Detection
CeriBell Inc. (CBLL) has received FDA Breakthrough Device Designation for its AI-based Large Vessel Occlusion (LVO) stroke detection and monitoring solution for hospital use. This designation accelerates the regulatory pathway for CBLL's technology, which leverages existing point-of-care EEG hardware and an AI algorithm to identify severe strokes earlier. The company's stock rose following the announcement, reinforcing its position in neurological monitoring.
Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution
Ceribell has received FDA Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection and monitoring solution for hospital patients. This solution uses Ceribell's existing hardware with an AI-based algorithm to interpret EEG signals for early detection of LVO stroke, which disproportionately causes higher morbidity and mortality. The company aims to address significant delays in in-hospital stroke detection and treatment, recognizing that timely intervention can greatly improve patient outcomes.
Ceribell, Inc. Receives FDA Breakthrough Device Designation for LVO Stroke Solution
Ceribell, Inc. announced on January 5, 2026, that its LVO stroke detection monitor received FDA Breakthrough Device Designation. This makes it the first point-of-care EEG technology approved for LVO stroke detection in hospitals, utilizing AI to interpret EEG signals for early detection. The designation highlights the device's potential to significantly improve outcomes for in-hospital stroke patients by offering timely and accurate detection.
FDA grants breakthrough designation to Ceribell’s stroke detection tool
Ceribell has received breakthrough device designation from the FDA for its LVO Stroke detection tool, which utilizes AI-based algorithms with its existing EEG monitoring platform. This designation aims to improve early detection of large vein occlusion stroke in hospitalized patients, an area where timely intervention significantly impacts patient outcomes. The news led to a rise in Ceribell's stock, highlighting the potential for this technology to address critical delays in stroke diagnosis within hospitals.
FDA grants breakthrough designation for Ceribell’s stroke detection monitor
The FDA has granted Breakthrough Device Designation to Ceribell, Inc. for its Large Vessel Occlusion (LVO) stroke detection monitor, aimed at improving early diagnosis in hospital settings. This device uses existing EEG hardware with an AI-based algorithm to interpret brain signals and follows recent FDA clearances for seizure detection in neonates and delirium screening solutions. Despite not yet being profitable, Ceribell, valued at $790 million, shows strong growth and high gross profit margins, according to InvestingPro data.
FDA grants breakthrough designation to Ceribell’s stroke detection tool
The FDA has granted Breakthrough Device Designation to Ceribell's AI-based tool for detecting large vein occlusion (LVO) stroke in hospitalized patients, utilizing its existing EEG monitoring platform. This designation is expected to accelerate development and review, recognizing the potential for early and accurate detection, which is crucial given that in-hospital strokes often face significant delays in diagnosis and treatment. Following the announcement, Ceribell's shares rose by approximately 4%.
Ceribell’s LVO Stroke Detection Monitor Wins FDA Breakthrough Nod
Ceribell has received FDA breakthrough device status for its large vessel occlusion (LVO) stroke detection monitor, which uses existing hardware and an AI-based algorithm to interpret EEG signals for early LVO stroke detection in hospital settings. This recognition highlights the monitor's potential for timely and accurate detection, addressing the significant delays in treating in-hospital strokes compared to community-onset cases. The breakthrough status builds upon Ceribell’s previous approvals for its neuro-monitoring technology.
Ceribell gets FDA breakthrough nod for stroke detection, monitoring solution
Ceribell received FDA breakthrough device designation for its large vessel occlusion (LVO) stroke detection monitor, which uses an AI-based algorithm to interpret EEG signals. This milestone expands the uses of Ceribell's point-of-care EEG brain monitoring technology, following recent FDA clearances for delirium and neonatal seizure monitoring solutions. The company emphasizes the potential of its system to provide timely detection of LVO strokes, a critical factor given their high morbidity and mortality rates.
FDA highlights new brain monitor that may spot deadly hospital strokes sooner
Ceribell (NASDAQ: CBLL) has received FDA Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection and monitoring solution for hospital patients. This innovative monitor utilizes Ceribell's existing point-of-care EEG hardware combined with an AI algorithm, building on previous 510(k) clearances for neonatal seizure and delirium screening solutions. The designation aims to improve the timely detection of in-hospital strokes, a population that accounts for up to 17% of U.S. strokes, where delays often lead to worse outcomes.
Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution
Ceribell has received FDA Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection monitor, utilizing an AI-based algorithm with its existing EEG hardware. This development aims to provide timely detection of LVO strokes, which have higher morbidity and mortality, especially for in-hospital patients where delays in diagnosis are common. The company hopes this will enable earlier intervention and better outcomes for patients.
Ceribell director resigns to pursue other professional ventures
Ceribell, Inc. announced that director Lucian Iancovici resigned from the Board of Directors and other committee roles, effective December 31, 2025, to focus on other professional ventures. The company confirmed his departure was amicable and not due to any disagreement with Ceribell’s operations or policies. Analysts currently rate CBLL as a Buy with a $30.00 price target, while TipRanks’ AI Analyst, Spark, rates it as Neutral due to profitability and valuation challenges despite strong technical momentum.
Geribell director Lucian Iancovici resigns from board and committees
Lucian Iancovici has resigned from Ceribell, Inc.'s board of directors, effective December 31, 2025, also stepping down from the Nominating and Corporate Governance Committee and Compensation Committee. His departure was not due to any disagreements with the company's operations or policies. Ceribell (NASDAQ: CBLL) recently achieved FDA clearance for its delirium monitoring system and its AI-powered seizure detection algorithm for newborns, leading to increased price targets from analysts and continued growth in the medical technology sector.
Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Ceribell, Inc. (Nasdaq: CBLL), a medical technology company focusing on neurological conditions, announced that CEO Jane Chao, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Monday, January 12, 2026, at 9:00 am PST / 12:00 pm EST, with a webcast available on Ceribell's investor relations website. Ceribell specializes in the Ceribell System, an FDA-cleared, AI-powered EEG platform for rapid diagnosis and monitoring of seizure and delirium in acute care settings.
Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Ceribell announced that its CEO and Co-founder, Jane Chao, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 9:00 am PST. The medical technology company, focused on neurological conditions, will make a live and archived webcast of the presentation available on its investor relations website. Ceribell specializes in the Ceribell System, an FDA-cleared point-of-care EEG platform utilizing AI for rapid diagnosis and continuous monitoring in acute care settings.
Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Ceribell, Inc. (Nasdaq: CBLL) announced that its CEO and Co-founder, Jane Chao, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. The presentation will cover Ceribell's focus on transforming the diagnosis and management of patients with serious neurological conditions using its FDA-cleared, AI-powered electroencephalography (EEG) platform. A webcast of the presentation will be available on the company's investor relations website.
Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Ceribell, Inc. announced that its CEO and Co-founder, Jane Chao, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The company, focused on neurological condition diagnosis and management with its FDA-cleared Ceribell System, will make the presentation available via webcast.
Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Ceribell, Inc. announced its CEO and Co-founder, Jane Chao, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The company, focused on neurological conditions, will discuss its Ceribell System, an FDA-cleared point-of-care EEG platform. A webcast of the presentation will be available on the company's investor relations website.
